

iScience, Volume 26

Supplemental information

Timed exercise stabilizes behavioral rhythms

but not molecular programs

in the brain's suprachiasmatic clock

Timna Hitrec, Cheryl Petit, Emily Cryer, Charlotte Muir, Natalie Tal, Jean-Michel Fustin, Alun T.L. Hughes, and Hugh D. Piggins




Figure S1. Principal component analysis (PCA) of RNAseq gene expression data, related to Figure 3. Most genotype and/or experimental condition samples appear to cluster. Data were analyzed by DeSeq2 method (see Methods section for further details).

a *Vipr2*^{-/-} vs *Vipr2*^{+/+} nSVE

| KEGG pathway | Name | q-value | Gene count | Direction of regulation |
|--------------|--------------------------------------|-------------|------------|-------------------------|
| mmu05034 | Alcoholism | 0.004740334 | 8 | Upregulated |
| mmu05031 | Amphetamine addiction | 0.004740334 | 5 | Upregulated |
| mmu04726 | Serotonergic synapse | 0.006340219 | 6 | Upregulated |
| mmu04728 | Dopaminergic synapse | 0.006340219 | 6 | Upregulated |
| mmu05030 | Cocaine addiction | 0.006340219 | 4 | Upregulated |
| mmu04724 | Glutamatergic synapse | 0.016077478 | 5 | Upregulated |
| mmu04926 | Relaxin signaling pathway | 0.025084251 | 5 | Upregulated |
| mmu04723 | Retrograde endocannabinoid signaling | 0.035810389 | 5 | Upregulated |
| mmu04727 | GABAergic synapse | 0.035810389 | 4 | Upregulated |
| mmu05032 | Morphine addiction | 0.035810389 | 4 | Upregulated |

b *Vipr2*^{+/+} SVE vs nSVE

| KEGG pathway | Name | q-value | Gene count | Direction of regulation |
|--------------|---------------------------------------|-------------|------------|-------------------------|
| mmu04360 | Axon guidance | 7.67408E-07 | 20 | Upregulated |
| mmu04724 | Glutamatergic synapse | 0.117552692 | 9 | Upregulated |
| mmu00515 | Mannose type O-glycan biosynthesis | 0.124383602 | 4 | Upregulated |
| mmu04390 | Hippo signaling pathway | 0.124383602 | 10 | Upregulated |
| mmu04929 | GnRH secretion | 0.124383602 | 6 | Upregulated |
| mmu04260 | Cardiac muscle contraction | 0.124383602 | 7 | Upregulated |
| mmu04727 | GABAergic synapse | 0.124383602 | 7 | Upregulated |
| mmu04930 | Type II diabetes mellitus | 0.124383602 | 5 | Upregulated |
| mmu04666 | Fc gamma R-mediated phagocytosis | 0.124383602 | 7 | Upregulated |
| mmu03010 | Ribosome | 3.21762E-13 | 22 | Downregulated |
| mmu05171 | Coronavirus disease - COVID-19 | 1.34363E-10 | 22 | Downregulated |
| mmu03060 | Protein export | 0.000129682 | 6 | Downregulated |
| mmu04070 | Phosphatidylinositol signaling system | 0.002133273 | 8 | Downregulated |
| mmu05016 | Huntington disease | 0.072831157 | 11 | Downregulated |
| mmu00562 | Inositol phosphate metabolism | 0.072831157 | 5 | Downregulated |
| mmu05017 | Spinocerebellar ataxia | 0.072831157 | 7 | Downregulated |
| mmu05012 | Parkinson disease | 0.072831157 | 10 | Downregulated |
| mmu05020 | Prion disease | 0.072831157 | 10 | Downregulated |
| mmu05014 | Amyotrophic lateral sclerosis | 0.07895987 | 12 | Downregulated |

c *Vipr2*^{-/-} SVE v nSVE

| KEGG pathway | Name | q-value | Gene count | Direction of regulation |
|--------------|--|-----------|------------|-------------------------|
| mmu04150 | mTOR signaling pathway | 0.0398956 | 5 | Upregulated |
| mmu01521 | EGFR tyrosine kinase inhibitor resistance | 0.1113208 | 3 | Upregulated |
| mmu04022 | cGMP-PKG signaling pathway | 0.1113208 | 4 | Upregulated |
| mmu05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 0.1113208 | 3 | Upregulated |
| mmu04010 | MAPK signaling pathway | 0.1113208 | 5 | Upregulated |
| mmu04666 | Fc gamma R-mediated phagocytosis | 0.1113208 | 3 | Upregulated |
| mmu01522 | Endocrine resistance | 0.1113208 | 3 | Upregulated |
| mmu05231 | Choline metabolism in cancer | 0.1127478 | 3 | Upregulated |
| mmu04625 | C-type lectin receptor signaling pathway | 0.1450173 | 3 | Upregulated |
| mmu04919 | Thyroid hormone signaling pathway | 0.1496492 | 3 | Upregulated |
| mmu03010 | Ribosome | 4.677E-06 | 10 | Downregulated |
| mmu05171 | Coronavirus disease - COVID-19 | 4.711E-05 | 10 | Downregulated |
| mmu05012 | Parkinson disease | 0.000471 | 9 | Downregulated |
| mmu05415 | Diabetic cardiomyopathy | 0.0005179 | 8 | Downregulated |
| mmu05208 | Chemical carcinogenesis - reactive oxygen species | 0.0005973 | 8 | Downregulated |
| mmu00190 | Oxidative phosphorylation | 0.001612 | 6 | Downregulated |
| mmu05020 | Prion disease | 0.001612 | 8 | Downregulated |
| mmu05016 | Huntington disease | 0.0031648 | 8 | Downregulated |
| mmu04714 | Thermogenesis | 0.0031648 | 7 | Downregulated |
| mmu05022 | Pathways of neurodegeneration - multiple diseases | 0.0111819 | 9 | Downregulated |

d *Vipr2*^{-/-} SVE vs *Vipr2*^{+/+} nSVE

| KEGG pathway | Name | q-value | Gene count | Direction of regulation |
|--------------|---|-------------|------------|-------------------------|
| mmu04360 | Axon guidance | 0.000616622 | 11 | Upregulated |
| mmu04727 | GABAergic synapse | 0.000616622 | 8 | Upregulated |
| mmu04270 | Vascular smooth muscle contraction | 0.001598807 | 9 | Upregulated |
| mmu04723 | Retrograde endocannabinoid signaling | 0.001598807 | 9 | Upregulated |
| mmu04012 | ErbB signaling pathway | 0.001598807 | 7 | Upregulated |
| mmu04921 | Oxytocin signaling pathway | 0.00166113 | 9 | Upregulated |
| mmu04912 | GnRH signaling pathway | 0.001676455 | 7 | Upregulated |
| mmu05032 | Morphine addiction | 0.001676455 | 7 | Upregulated |
| mmu04010 | MAPK signaling pathway | 0.002062915 | 12 | Upregulated |
| mmu04726 | Serotonergic synapse | 0.002062915 | 8 | Upregulated |
| mmu03010 | Ribosome | 9.95815E-21 | 30 | Downregulated |
| mmu05171 | Coronavirus disease - COVID-19 | 6.36224E-18 | 31 | Downregulated |
| mmu05020 | Prion disease | 3.93115E-07 | 20 | Downregulated |
| mmu05016 | Huntington disease | 4.17547E-07 | 21 | Downregulated |
| mmu05012 | Parkinson disease | 1.06235E-06 | 19 | Downregulated |
| mmu00190 | Oxidative phosphorylation | 5.86812E-06 | 13 | Downregulated |
| mmu05208 | Chemical carcinogenesis - reactive oxygen species | 1.02868E-05 | 16 | Downregulated |
| mmu05010 | Alzheimer disease | 1.23341E-05 | 21 | Downregulated |
| mmu04714 | Thermogenesis | 1.37033E-05 | 16 | Downregulated |
| mmu05014 | Amyotrophic lateral sclerosis | 2.28721E-05 | 20 | Downregulated |

Figure S2. KEGG pathways, related to Figure 3. The top 10 up-regulated and down-regulated terms in the KEGG database for functional enrichment of genes (Kyoto Encyclopedia of Genes and Genomes). In panel a., no KEGG terms were significantly down-regulated.




Figure S3. Top20 most differentially regulated genes and top10 most enriched Gene Ontology terms across the genotype and conditions, related to Figure 3. Left: Heatmap depicting the 20 most significantly differentially expressed genes in the *Vipr2*^{-/-} vs *Vipr2*^{+/+} nSVE, *Vipr2*^{+/+} SVE vs nSVE *Vipr2*^{-/-} SVE vs nSVE and *Vipr2*^{-/-} SVE vs *Vipr2*^{+/+} nSVE comparisons. The colour intensity was calculated by dividing the gene count of each individual animal with the average for the whole cohort (1=100% of mean value, the darker the colour, the more up-regulated expression in the sample). **Right:** The 10 most enriched terms in the Biological Process of the Gene Ontology Enrichment Analysis. The size of the circle is a representation of the number of genes that have been annotated, whereas the colour is indicative of the q-value.




Figure S4. Heatmap of core clock gene expression, related to Figure 4. Heatmap depicting changes in core clock gene expression quantified in RNAseq investigation in the suprachiasmatic nucleus of *Vipr2*^{+/+} and *Vipr2*^{-/-} mice under nSVE and SVE conditions. The gene expression for each animal was normalized to the gene's average value in the entire dataset and expressed as Log10 (with the average value=1), darker colours indicate an above average expression, whereas lighter shades correspond to below average expression.




Figure S5. RNAseq gene expression counts of an expanded selection of genes that are differentially expressed across genotype and condition, related to Figure 4. Genes have been grouped by significance comparisons as illustrated in the Venn diagram on the right. For example, *Per2* is amongst the 52 genes (d) that are differentially expressed in the comparisons $Vipr2^{-/-}$ vs $Vipr2^{+/+}$ nSVE and $Vipr2^{+/+}$ SVE vs nSVE (intersection between the yellow and blue sets). Points show each animal's gene expression count with bars denoting mean value \pm SEM. (q value <0.05 = *, <0.01 = **, <0.005 = ***, <0.001 = ****).




Figure S6. RNAseq gene expression counts of genes known to be enriched in the SCN across the animals, related to Figure 4. RNAseq gene counts were normalised using the built-in normalisation method in DeSeq2. A quantification of the genes described in the meta-analysis of Brown et al.¹²⁷, except for RP24-361E14.1, is shown. All genes were found to be expressed in each sample, suggesting that the SCN was sampled consistent with other studies. The values are expressed as percentage of the mean value across all samples.